NRSNNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NRSNW
NeuroSense Therapeutics Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$2.67−0.40 (-13.19%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns NeuroSense Therapeutics's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
2 buys · 0 sales
Net bought $400.00K
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Alon Ben-Noon | 3,072,600 | 19.98% | 13G (passive) amendment | Dec 31, 2023 |
| Rimon Gold Assets Ltd. | 2,303,729 | 9.99% | 13G (passive) | Dec 9, 2024 |
| Ariel Gordon | 1,060,561 | 6.90% | 13G (passive) amendment | Dec 31, 2023 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Alon Ben-Noon | Chief Executive Officer | 4,534,233 | Jun 17, 2026 |
| Or Eisenberg | Chief Financial Officer | 1,504,050 | Jun 17, 2026 |
| Niva Russek-Blum | Chief Technology Officer | 39,881 | Mar 30, 2026 |
| Hagit Binder | General Manager | 521,806 | Mar 30, 2026 |
| Ferenc Tracik | Chief Medical Officer | 189,618 | Mar 18, 2026 |
| Revital Mandil-Levin | Director | 52,526 | Mar 31, 2026 |
| Mark Leuchtenberger | Director | 128,000 | Mar 18, 2026 |
| Cary J. Claiborne | Director | 60,000 | Mar 18, 2026 |
| Roy Golan | Director | 60,000 | Mar 18, 2026 |
| Christine A. Pellizzari | Director | 99,898 | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Alon Ben-Noon Chief Executive Officer | Jun 16, 2026 | Buy | +250,000 | $0.80 | $200.00K | 4,534,233 |
| Or Eisenberg Chief Financial Officer | Jun 16, 2026 | Buy | +250,000 | $0.80 | $200.00K | 1,504,050 |
| Or Eisenberg Chief Financial Officer | Mar 26, 2026 | Award | +200,000 | – | – | 1,254,050 |
| Niva Russek-Blum Chief Technology Officer | Mar 26, 2026 | Award | +200,000 | – | – | 467,953 |
| Hagit Binder General Manager | Mar 26, 2026 | Award | +200,000 | – | – | 521,806 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.